Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma
Cancers · 24.10.2023 · 15 (21) · 5117
DOI: 10.3390/cancers15215117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.10.2023. Verfasst von Nanami L Miyazaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NCI NIH HHS, National Institutes of Health, National Cancer Institute, Center for Cancer Research.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) contribute to a significant global cancer burden. Developments in current therapeutic approaches have improved patient outcomes but have limited efficacy in patients with unresectable and/or recurrent HNSCC. RM-1929 near-infrared photoimmunotherapy (NIR-PIT) is an emerging treatment that is currently being investigated in a Phase III clinical trial and has been conditionally approved for the treatment of unresectable and/or recurrent HNSCC in Japan. Here, we collect a series of case reports and clinical trial data to assess the efficacy of RM-1929 NIR-PIT. Disease control rates ranged from 66.7 to 100% across these studies, and overall response rates ranged from 43.3 to 100%, suggesting positive clinical outcomes. Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Aki Furusawa, Peter L Choyke, Hisataka Kobayashi
Förderung
- Intramural NIH HHS
- NCI NIH HHS
- National Institutes of Health, National Cancer Institute, Center for Cancer Research
Zitieren
APA
Miyazaki, N. L., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2023). Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers, 15(21), 5117. https://doi.org/10.3390/cancers15215117
Vancouver
Miyazaki NL, Furusawa A, Choyke PL, Kobayashi H. Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers. 2023;15(21):5117. doi:10.3390/cancers15215117
BibTeX
@article{Miyazaki2023,
author = {Miyazaki, Nanami L and Furusawa, Aki and Choyke, Peter L and Kobayashi, Hisataka},
title = {Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {21},
pages = {5117},
doi = {10.3390/cancers15215117}
}
EUVIMED